Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.51 |
| ▸ | CNR2 | P34972 | 13/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349339 | 0.88 | CNR2 (0.49) | CNR1CNR2KMT2AHCAR3 | |
| SCHEMBL29951395 | 0.88 | CNR2 (0.49) | CNR1CNR2KMT2AHCAR3 | |
| SCHEMBL3350909 | 0.84 | KDM4E (0.46) | CNR1CNR2HCAR3 | |
| SCHEMBL4899436 | 0.84 | CNR2 (0.53) | CNR1CNR2KMT2A | |
| SCHEMBL1552793 | 0.78 | PDE4A (0.62) | CNR1CNR2HCAR3 | |
| Hydrochloric Acid SCHEMBL8605727 | 0.77 | PDE4A (0.61) | CNR1CNR2HCAR3 | |
| SCHEMBL27679944 | 0.76 | SLC22A12 (0.50) | KMT2AHCAR3 | |
| SCHEMBL2642659 | 0.76 | CNR2 (0.51) | CNR1CNR2 | |
| SCHEMBL11979708 | 0.76 | CNR1 (0.81) | CNR1CNR2KMT2A | |
| SCHEMBL3350382 | 0.75 | CNR1 (0.50) | CNR1CNR2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | PFIZER INC. | 2008-06-05 | — | — | US | claimed |
| EP-1794114-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032999-A1 | N-METHYL HYDROXYETHYLAMINE USEFUL IN TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | PFIZER INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132552-A1 | N-methyl hydroxyethylamine useful in treating CNS conditions | HNMT, PNMT, BHMT | CNR1 256/4885CNR2 222/4885KMT2A 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.